Moxifloxacine Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacine Fresenius Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH USA supplies Moxifloxacine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibacterial indicated for several serious infections.

Community‑acquired bacterial pneumonia: effective in treating adult patients with typical and atypical pathogens. Complicated intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms. Acute bacterial sinusitis: reduces symptoms and bacterial load in acute sinus infections. Acute bacterial exacerbation of chronic bronchitis: improves lung function and reduces exacerbation duration. Skin and skin structure infections: active against common Gram‑positive and Gram‑negative skin pathogens.

Moxifloxacin may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Diarrhea or loose stools - Headache - Dizziness or vertigo - Injection site pain or erythema - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis, especially in the Achilles tendon - QT interval prolongation and potential arrhythmias - Clostridioides difficile‑associated colitis - Severe hypersensitivity reactions, including Stevens‑Johnson syndrome - Anaphylaxis or anaphylactoid reactions - Peripheral neuropathy or visual disturbances

Moxifloxacin requires careful patient assessment before use.

Assess renal function: adjust therapy if significant impairment is present. Monitor liver enzymes: watch for hepatotoxicity during prolonged treatment. Evaluate QT prolongation risk: avoid in patients with known cardiac conduction abnormalities. Avoid use in patients with known hypersensitivity to fluoroquinolones. Use with caution in elderly patients due to increased tendon injury risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes.

Major Interactions (Avoid): - Concomitant QT‑prolonging agents (e.g., macrolides, antiarrhythmics) may increase arrhythmia risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) can heighten seizure potential. - Antacids or supplements containing magnesium/aluminum may reduce absorption. - Warfarin: may enhance anticoagulant effect and increase bleeding risk. - Cyclosporine: may raise cyclosporine plasma concentrations.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use may raise tendon rupture risk. - Theophylline: moxifloxacin can increase theophylline levels, requiring monitoring. - Oral contraceptives: efficacy may be reduced, advise backup contraception. - Diabetic agents: potential for hypoglycemia, monitor blood glucose. - Certain antidiabetic sulfonylureas: may increase hypoglycemic episodes.